Table 6. Significant predictors of ESKD at follow-up.
| Risk factors | Univariate P value | Multivariable regression | |||
|---|---|---|---|---|---|
| Exp (B) | 95% C.I. | P value | |||
| Lower | Upper | ||||
| Gender | 0.22 | ||||
| Renal symptoms
Oliguria Yes Anuria Yes Uremic symptoms Yes |
<0.001 0.004 <0.001 |
|
1.7 |
6.7 |
<0.001 |
| Extra-renal symptoms
Skin lesions No Arthritis No |
0.038 0.014 |
||||
| Serum creatinine (mg/dL) | <0.001 | ||||
| CKD-EPI eGFR (ml/min/1.73m2) | <0.001 | ||||
| Normal C3 | 0.66 | ||||
| Normal C4 | 0.04 | ||||
| Serology
ANA neg. Anti- dsDNA pos. ANCA pos. |
0.014 0.07 0.68 |
||||
| Percentage of crescents | <0.001 | 1.02 | 1.005 | 1.04 | 0.01 |
| Glomerular lesions
Mesangial proliferation No Predominant type of crescents Cellular Yes Vascular Necrosis Yes Interstitial IFTA Moderate/Severe Yes |
0.01 0.28 0.022 <0.001 |
3.4 |
1.8 |
6.5 |
<0.001 |
| Type I/III Cr.GN | <0.001 | 2.7 | 1.4 | 5.1 | 0.003 |
| Immunosuppression No | 0.003 | ||||
| PLEX Yes | 0.1 | ||||
| Hemodialysis at index visit discharge Yes | <0.001 | ||||
Abbreviations: ANA, anti-nuclear antibody; ANCA, anti-neutrophil cytoplasmic antibody; C3, complement C3; C4, complement C4; IFTA, interstitial fibrosis and tubular atrophy; PLEX, plasma exchange; CR.GN, crescentic glomerulonephritis; eGFR, estimated glomerular filtration rate (calculated using the CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration formula).